{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T11:59:26Z","timestamp":1788609566272,"version":"build-2803163510"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,2,3]],"date-time":"2017-02-03T00:00:00Z","timestamp":1486080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,2,3]],"date-time":"2017-02-03T00:00:00Z","timestamp":1486080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s00417-017-3603-3","type":"journal-article","created":{"date-parts":[[2017,2,2]],"date-time":"2017-02-02T23:18:32Z","timestamp":1486077512000},"page":"1221-1228","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Rituximab in the treatment of ocular cicatricial pemphigoid: a retrospective cohort study"],"prefix":"10.1007","volume":"255","author":[{"given":"Caiyun","family":"You","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neerav","family":"Lamba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres F.","family":"Lasave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail Hernandez","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Stephen","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,2,3]]},"reference":[{"issue":"4","key":"3603_CR1","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/S0161-6420(79)35486-0","volume":"86","author":"BJ Mondino","year":"1979","unstructured":"Mondino BJ, Brown SI, Lempert S, Jenkins MS (1979) The acute manifestations of ocular cicatricial pemphigoid: diagnosis and treatment. Ophthalmology 86(4):543\u2013555","journal-title":"Ophthalmology"},{"key":"3603_CR2","first-page":"527","volume":"84","author":"CS Foster","year":"1986","unstructured":"Foster CS (1986) Cicatricial pemphigoid. Trans Am Ophthalmol Soc 84:527\u2013663","journal-title":"Trans Am Ophthalmol Soc"},{"issue":"6","key":"3603_CR3","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/S0161-6420(91)32209-7","volume":"98","author":"R Neumann","year":"1991","unstructured":"Neumann R, Tauber J, Foster CS (1991) Remission\u2002and\u2002recurrence\u2002after\u2002withdrawal\u2002of\u2002therapy for\u2002ocular cicatricial pemphigoid. Ophthalmology 98(6):858\u2013862","journal-title":"Ophthalmology"},{"issue":"5","key":"3603_CR4","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.ophtha.2009.09.049","volume":"117","author":"CS Foster","year":"2010","unstructured":"Foster CS, Chang PY, Ahmed AR (2010) Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid: a preliminary report. Ophthalmology 117(5):861\u2013869","journal-title":"Ophthalmology"},{"issue":"5","key":"3603_CR5","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1007\/s00296-011-2126-1","volume":"32","author":"A Heiligenhaus","year":"2012","unstructured":"Heiligenhaus A, Michels H, Schumacher C, Kopp I, Neudorf U, Niehues T, Baus H, Becker M, Bertram B, Dannecker G, Deuter C, Foeldvari I, Frosch M, Ganser G, Gaubitz M, Gerdes G, Horneff G, Illhardt A, Mackensen F, Minden K, Pleyer U, Schneider M, Wagner N, Zierhut M (2012) Evidence-based, interdisciplinary guidelines for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis. Rheumatol Int 32(5):1121\u20131133","journal-title":"Rheumatol Int"},{"issue":"7","key":"3603_CR6","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1136\/ard.2004.027128","volume":"64","author":"K Ahmadi-Simab","year":"2005","unstructured":"Ahmadi-Simab K, Lamprecht P, N\u00f6lle B, Ai M, Gross WL (2005) Successful treatment of refractory anterior scleritis in primary Sjogren\u2019s syndrome with rituximab. Ann Rheum Dis 64(7):1087\u20131088","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"3603_CR7","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1016\/j.ophtha.2015.01.016","volume":"122","author":"L Joshi","year":"2015","unstructured":"Joshi L, Tanna A, McAdoo SP, Medjeral-Thomas N, Taylor SR, Sandhu G, Tarzi RM, Pusey CD, Lightman S (2015) Long-term outcomes of rituximab therapy in ocular granulomatosis with polyangiitis: impact on localized and nonlocalized disease. Ophthalmology 122(6):1262\u20131268","journal-title":"Ophthalmology"},{"issue":"1","key":"3603_CR8","first-page":"1","volume":"5","author":"JD Peterson","year":"2009","unstructured":"Peterson JD, Chan LS (2009) Effectiveness and side effects of anti-CD20 therapy for autoantibody-mediated blistering skin diseases: acomprehensive survey of 71 consecutive patients from the Initial use to 2007. Ther Clin Risk Manag 5(1):1\u20137","journal-title":"Ther Clin Risk Manag"},{"issue":"4","key":"3603_CR9","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.autrev.2014.12.002","volume":"14","author":"AR Ahmed","year":"2015","unstructured":"Ahmed AR, Shetty S (2015) A comprehensive analysis of treatment of outcomes in patients with pemphigus vulgaris treated with rituximab. Autoimmun Rev 14(4):323\u2013331","journal-title":"Autoimmun Rev"},{"issue":"7","key":"3603_CR10","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1001\/jamadermatol.2013.6739","volume":"150","author":"K Heelan","year":"2014","unstructured":"Heelan K, Al-Mohammedi F, Smith MJ, Knowles S, Lansang P, Walsh S, Shear NH (2014) Durable remission of pemphigus with a fixed-dose rituximab protocol. JAMA Dermatol 150(7):703\u2013708","journal-title":"JAMA Dermatol"},{"issue":"3","key":"3603_CR11","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.jaad.2012.10.018","volume":"68","author":"S Shetty","year":"2013","unstructured":"Shetty S, Ahmed AR (2013) Critical analysis of the use of rituximab in mucous membrane pemphigoid: a review of the literature. J Am Acad Dermatol 68(3):499\u2013506","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"3603_CR12","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.jaad.2013.01.046","volume":"69","author":"K Heelan","year":"2013","unstructured":"Heelan K, Walsh S, Shear NH (2013) Treatment of mucous membrane pemphgoid with rituximab [letters]. J Am Acad Dermatol 69(2):310\u2013311","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"3603_CR13","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1517\/14712598.2015.1046833","volume":"15","author":"A R\u00fcbsam","year":"2015","unstructured":"R\u00fcbsam A, Stefaniak R, Worm M, Pleyer U (2015) Rituximab preserves vision in ocular mucous membrane pemphigoid. Expert Opin Biol Ther 15(7):927\u2013933","journal-title":"Expert Opin Biol Ther"},{"issue":"7","key":"3603_CR14","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/archdermatol.2011.54","volume":"147","author":"C Le Roux-Villet","year":"2011","unstructured":"Le Roux-Villet C, Prost-Squarcioni C, Alexandre M, Caux F, Pascal F, Doan S, Brette MD, Soued I, Gabison \u00c9, Aucouturier F, Letestu R, Laroche L, Bachelez H (2011) Rituximab for patients with refractory mucous membrane pemphigoid. Arch Dermatol 147(7):843\u2013849","journal-title":"Arch Dermatol"},{"issue":"5","key":"3603_CR15","first-page":"45","volume":"6","author":"U Wollina","year":"2013","unstructured":"Wollina U, Pabst F, Kuss H, Tilp M, Runge J (2013) Monoclonal anti-CD20 antibody therapy in, Cicatrical pemphigoid with oral and hypopharyngeal involvementand related conditions [letters]. J Clin Aesthet Dermatol 6(5):45\u201348","journal-title":"J Clin Aesthet Dermatol"},{"issue":"1","key":"3603_CR16","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3315\/jdcr.2008.1007","volume":"2","author":"U Wollina","year":"2008","unstructured":"Wollina U, Koch A, Hansel G (2008) Rituximab therapy of recalcitrant bullous dermatoses. J Dermatol Case Rep 2(1):4\u20137","journal-title":"J Dermatol Case Rep"},{"issue":"1","key":"3603_CR17","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2340\/00015555-0560","volume":"89","author":"T Schumann","year":"2009","unstructured":"Schumann T, Schmidt E, Booken N, Goerdt S, Goebeler M (2009) Successful treatment of mucous membrane pemphigoid with the anti-CD20 antibody rituximab [letters]. Acta Derm Venereol 89(1):101\u2013102","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"3603_CR18","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1111\/j.1365-2133.2006.07646.x","volume":"156","author":"E Schmidt","year":"2007","unstructured":"Schmidt E, Seitz CS, Benoit S, Br\u00f6cker EB, Goebeler M (2007) Rituximab in autoimmune bullous diseases: mixed responses and adverse effects. Br J Dermatol 156(2):352\u2013356","journal-title":"Br J Dermatol"},{"issue":"10","key":"3603_CR19","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1111\/j.1468-3083.2010.03889.x","volume":"25","author":"S Lourari","year":"2011","unstructured":"Lourari S, Herve C, Doffoel-Hantz V, Meyer N, Bulai-Livideanu C, Viraben R, Maza A, Adoue D, Bedane C, Paul C (2011) Bullous and mucous membrane pemphigoid show a mixed response to rituximab: experience in seven patients. J Eur Acad Dermatol Venereol 25(10):1238\u20131240","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"3603_CR20","first-page":"731","volume":"6","author":"JA Taverna","year":"2007","unstructured":"Taverna JA, Lerner A, Bhawan J, Demierre MF (2007) Successful adjuvant treatment of recalcitrant mucous membrane pemphigoid with anti-CD20 antibody rituximab. J Drugs Dermatol 6(7):731\u2013732","journal-title":"J Drugs Dermatol"},{"key":"3603_CR21","doi-asserted-by":"crossref","unstructured":"Ross AH, Jaycock P, Cook SD, Dick AD, Tole DM.(2009) The use of rituximab in refractory mucous membrane pemphigoid with severe ocular involvement. Br J Ophthalmol;93(4):421\u2013422, 548.","DOI":"10.1136\/bjo.2007.129510"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-017-3603-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-017-3603-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-017-3603-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T00:46:55Z","timestamp":1659055615000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-017-3603-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,3]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["3603"],"URL":"https:\/\/doi.org\/10.1007\/s00417-017-3603-3","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,3]]},"assertion":[{"value":"28 September 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"No funding was received for this research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers\u2019 bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. For this type of study formal consent is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}